Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status approved; investigational
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 61200-002; 65344-0029; 54245-1359; 60505-4512; 69339-168; 50742-366; 67184-0531; 0310-0482; 53104-7700; 63850-8070; 0480-4053; 68554-0060; 73377-128; 54893-0036
UNII S65743JHBS
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Corneal disorder06.08.01.004--Not Available
Blood disorder01.05.01.004--Not Available
Bone lesion15.02.04.0160.000112%Not Available
Disease progression08.01.03.0380.004253%
Disease recurrence08.01.03.0500.000168%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Metastasis16.22.01.0010.000336%Not Available
Cystitis noninfective20.03.02.001--
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000112%Not Available
Malignant transformation16.16.01.0130.000951%Not Available
Bone marrow failure01.03.03.0050.000448%
Liver injury12.01.17.012; 09.01.07.0220.000168%Not Available
Ocular ischaemic syndrome24.04.09.005; 06.07.02.005--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000504%Not Available
Sinus node dysfunction02.03.03.017--
Multiple organ dysfunction syndrome08.01.03.0570.000280%
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.000112%Not Available
Lung carcinoma cell type unspecified recurrent16.19.02.005; 22.08.01.0180.000280%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000112%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000168%Not Available
Metastases to adrenals16.22.02.012; 05.01.04.0070.000168%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.001511%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000168%Not Available
Metastases to pleura22.05.04.002; 16.22.02.0220.000224%Not Available
Metastases to the mediastinum22.09.03.009; 16.22.02.0270.000112%Not Available
Metastases to meninges16.22.02.003; 17.02.10.0120.001119%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000168%Not Available
Cutaneous symptom23.07.04.0230.000112%Not Available
Lung opacity22.12.01.0060.000112%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene